Telix Securities Class Action Reaches Lead-Plaintiff Deadline as Firms Press Investors to Act

The court will select a lead plaintiff to direct the case following investor motions due today.

Overview

Investors have until January 9, 2026 to move for appointment as lead plaintiff in the federal securities case against Telix.
The complaint alleges Telix and certain executives overstated progress on prostate cancer therapeutics and the reliability of third-party manufacturing and supply chain partners.
Telix disclosed on July 22, 2025 that it received an SEC subpoena focused on its development disclosures, after which its ADSs fell more than 13% over two trading sessions.
On August 28, 2025 the company reported an FDA Complete Response Letter for TLX250‑CDx citing CMC deficiencies and Form 483 notices at two third‑party sites, followed by a drop of more than 21% in the shares over two sessions.
Faruqi & Faruqi, The Gross Law Firm, Hagens Berman, and Levi & Korsinsky have issued reminders and are recruiting investors as the lawsuit proceeds.